Sign inCreate account

Report workspace

Add to folder
NCT02549261UNKNOWNanonymous

Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer

Sponsor

Source record

Biotech Pharmaceutical Co., Ltd.

Phase

Source record

NA

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

nimotuzumab, Cisplatin, Etoposide, radiotherapy

Indication / condition

AI-normalized

Non-small Cell Lung Cancer

Intervention

Source record

nimotuzumab, Cisplatin, Etoposide, radiotherapy

Related intelligence directories

Indication directory: Non-small Cell Lung CancerModality directory: monoclonal antibodyTarget directory: nimotuzumab

Source & freshness

Source record

NCT ID

NCT02549261

Original source

ClinicalTrials.gov

Source last updated

Sep 15, 2015

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02549261

Title

Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer

Sponsor

Biotech Pharmaceutical Co., Ltd.

Status

UNKNOWN

Phase

NA

Condition raw

Non-small Cell Lung Cancer

Condition normalized

Non-small Cell Lung Cancer

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

nimotuzumab, Cisplatin, Etoposide, radiotherapy

Target normalized

nimotuzumab, Cisplatin, Etoposide, radiotherapy

Interventions

nimotuzumab, Cisplatin, Etoposide, radiotherapy

Public preview

Source record

Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the efficacy and safety of the combination of Nimotuzumab administered concomitantly with chemoradiotherapy in patients with NSCLC .There is a tolerance trial of Nimotuzumab in Combination With Radiochemotherapy treatment before the randomization,double blind,muti-center sites trial of this treatment.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT02549261

Status

UNKNOWN

Phase

NA

Sponsor

Biotech Pharmaceutical Co., Ltd.

Executive brief

Investment-Ready Snapshot

Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the efficacy and safety of the combination of Nimotuzumab administered concomitantly with chemoradiotherapy in patients with NSCLC .There is a tolerance trial of Nimotuzumab in Combination With Radiochemotherapy treatment before the randomization,double blind,muti-center sites trial of this treatment.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 15, 2015
Internal syncJun 19, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02549261

Indication

Non-small Cell Lung Cancer

Modality

monoclonal antibody

Target

nimotuzumab, Cisplatin, Etoposide, radiotherapy

Intervention

nimotuzumab, Cisplatin, Etoposide, radiotherapy

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.